|
| | HR0450HAM003 | | LRB097 12219 RPM 59504 a |
|
|
| 1 | | AMENDMENT TO HOUSE RESOLUTION 450
|
| 2 | | AMENDMENT NO. ___. Amend House Resolution 450 by replacing |
| 3 | | everything after the title with the following:
|
| 4 | | "WHEREAS, In response to high costs for specialty-tier |
| 5 | | prescription drugs for chronically ill, insured patients, |
| 6 | | employer health plans and employer prescription drug plans have |
| 7 | | increased enrollee cost sharing amounts, instituted |
| 8 | | coinsurance, and implemented specialty tiers; and |
| 9 | | WHEREAS, The Medco 2011 Drug Trend Report showed that |
| 10 | | non-specialty medications grew at 1.1% in 2010 and specialty |
| 11 | | drugs grew at a pace of 17.4%; and |
| 12 | | WHEREAS, The price of specialty-tier drugs is often higher |
| 13 | | than traditional generics or branded medications and can create |
| 14 | | significant financial pressures on employer health plans, |
| 15 | | employer prescription drug plans, and individuals who purchase |
|
| | HR0450HAM003 | - 2 - | LRB097 12219 RPM 59504 a |
|
|
| 1 | | an individual health insurance policy; and |
| 2 | | WHEREAS, The National Conference of State Legislatures |
| 3 | | reports that between the years 2000 and 2009, copayments for
|
| 4 | | insured workers have increased for specialty-tier drugs; and |
| 5 | | WHEREAS, Medicare has used specialty tiers since 2006 to
|
| 6 | | help control prescription drug costs on behalf of taxpayers;
|
| 7 | | and
|
| 8 | | WHEREAS, Nationally, 11% of employers utilize a |
| 9 | | coinsurance
or percentage of the cost of fourth-tier or |
| 10 | | specialty-tier
prescription medications to help control the |
| 11 | | cost of their
prescription drug benefit plans; and |
| 12 | | WHEREAS, Specialty-tier medications are often life-saving |
| 13 | | drugs and include medications for chronic diseases, including |
| 14 | | certain types of cancer, hemophilia, multiple sclerosis, |
| 15 | | myositis, neuropathy, arthritis, human immunodeficiency virus, |
| 16 | | and other diseases and disorders and do not have brand or |
| 17 | | generic alternatives; and |
| 18 | | WHEREAS, Step therapy is a strategy offered by employer |
| 19 | | health plans and employer prescription drug plans to |
| 20 | | incentivize plan participants to utilize lower cost generics or |
| 21 | | preferred brand alternatives when available; and
|
|
| | HR0450HAM003 | - 3 - | LRB097 12219 RPM 59504 a |
|
|
| 1 | | WHEREAS, A specialty tier is a cost-sharing benefit |
| 2 | | structure utilized by employer health plans for prescription |
| 3 | | drugs that requires a consumer for any drug to pay a greater |
| 4 | | cost than that which applies for a non-preferred brand name |
| 5 | | drug; and |
| 6 | | WHEREAS, Specialty tier benefit structures may place |
| 7 | | financial burdens upon insured individuals with chronic health |
| 8 | | care issues requiring prescription medication, and may lead to |
| 9 | | decreased adherence or failure to take medications as |
| 10 | | prescribed, that may result in acute incidents and negative |
| 11 | | health outcomes such as doctor visits, emergency room visits, |
| 12 | | and hospital stays that can be much more expensive; therefore, |
| 13 | | be it
|
| 14 | | RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE
|
| 15 | | NINETY-SEVENTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that
|
| 16 | | the Department of Insurance shall (1) determine the impact a |
| 17 | | designed benefit plan that implements coinsurance for |
| 18 | | prescription medications has on individuals and employer |
| 19 | | health plans; (2) study the availability of manufacturer |
| 20 | | discounts and assistance plans to individuals and employers for |
| 21 | | specialty-tier medications; (3) determine the percentage of |
| 22 | | small group and large group health plans in this State |
| 23 | | providing prescription drug benefits and identify plan options |
|
| | HR0450HAM003 | - 4 - | LRB097 12219 RPM 59504 a |
|
|
| 1 | | used by employer health plans and individuals to assist them to |
| 2 | | contain the costs of their specialty drug benefits; and (4) |
| 3 | | identify and evaluate options for reducing any negative impacts |
| 4 | | of cost sharing, coinsurance, and specialty-tier pricing; and |
| 5 | | be it further |
| 6 | | RESOLVED, That the Department of Insurance shall report to
|
| 7 | | the General Assembly on the first day of November, 2012 on its |
| 8 | | findings, conclusions, and recommendations; and be it further |
| 9 | | RESOLVED, That a suitable copy of this resolution be
|
| 10 | | delivered to the Director of Insurance.".
|